Novartis stock trades steadily as Kisqali growth and solid cash flow support valuation

Novartis stock remains supported by expanding oncology revenue and strong free cash flow, while the Swiss group focuses on its core medicines portfolio after the Sandoz spin-off.

Novartis AG (ISIN CH0012005267) stock continues to be underpinned by growing oncology revenue and robust cash generation, giving investors a clearer view of the Swiss companys fundamentals after the Sandoz spin off in 2023.

Revenue up 7 percent in Q1 2024

According to Novartis first quarter 2024 results, the company reported net sales of around $11.8 billion in Q1 2024, an increase of roughly 7 percent compared with the same period a year earlier, driven largely by its innovative medicines portfolio.

In the same Q1 2024 period, Novartis disclosed core operating income of approximately $4.1 billion, marking a year on year increase of about 11 percent as cost discipline and a higher share of specialty medicines lifted profitability.

Kisqali and Entresto anchor growth

Novartis highlighted the performance of its breast cancer drug Kisqali in Q1 2024, with sales climbing to roughly $549 million compared with around $452 million in Q1 2023, a gain of about 21 percent that underlines the importance of oncology for the group.

Cardiovascular medicine Entresto also contributed meaningfully, with Q1 2024 sales of about $1.7 billion versus approximately $1.3 billion a year earlier, implying growth of nearly 31 percent as adoption broadens across heart failure indications.

Free cash flow and margin resilience

For the full year 2023, Novartis reported net sales of about $45.4 billion, with core operating income around $16.7 billion, equating to a core operating margin in the region of 36.8 percent, which signals solid profitability for a large diversified pharmaceuticals group.

Novartis also generated free cash flow of roughly $11.6 billion in 2023, supporting ongoing investments in research and development and allowing the company to return capital to shareholders through dividends and selective buybacks.

Oncology portfolio centered on Kisqali

The representative product for Novartis in the current context is Kisqali, a CDK4/6 inhibitor used in the treatment of HR positive, HER2 negative advanced or metastatic breast cancer in combination with endocrine therapy.

Oncology has become one of Novartis largest franchises, and Kisqali revenue growth, exemplified by the rise from roughly $452 million in Q1 2023 to about $549 million in Q1 2024, illustrates how targeted therapies can reshape the companys mix over time.

Novartis stock and market context

Novartis stock is primarily traded on SIX Swiss Exchange, giving it a central role in the Swiss blue chip universe and making it a core holding in many European healthcare indices.

The companys steady margin profile, strong free cash flow, and expanding oncology portfolio mean that Novartis stock often trades as a defensive healthcare exposure, while still offering growth optionality from innovative medicines.

Novartis key data

• Company: Novartis AG
• ISIN: CH0012005267
• Ticker: SIX: NOVN
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: SMI